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Abstract EmrE is a small multidrug transporter that contains
110 amino acid residues that form four transmembrane K-heli-
ces. The three-dimensional structure of EmrE has been deter-
mined from two-dimensional crystals by electron cryo-microsco-
py. EmrE is an asymmetric homo-dimer with one substrate
molecule bound in a chamber accessible laterally from one leaf-
let of the lipid bilayer. Evidence from substrate binding analyses
and analytical ultracentrifugation of detergent-solubilised EmrE
shows that the minimum functional unit for substrate binding is
a dimer. However, it is possible that EmrE exists as a tetramer
in vivo and plausible models are suggested based upon analyses
of two-dimensional crystals.
 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The incidence of Gram-negative pathogens resistant to a
large range of antibiotics is increasing and the resultant de¢cit
in e¡ective therapeutic strategies emphasises the urgent need
for novel therapeutic approaches to the treatment of infec-
tious disease [1]. To a large extent, multidrug and drug-spe-
ci¢c e¥ux systems in these pathogenic bacteria account for
their clinically signi¢cant resistance to therapeutic com-
pounds, and consequently have attracted the attention of
many research groups [2,3]. The e¥ux of toxic molecules is
driven either by ATP hydrolysis, as in the ABC transporter
superfamily, or by coupling e¥ux to the inward movement of
protons down their concentration gradient in an antiport
mechanism. Hþ-drug antiporters have evolved in many di¡er-
ent transporter families [4], including the major facilitator
superfamily, the resistance^nodulation^cell division family
and the small multidrug resistance (SMR) family. The SMR
family is composed of polytopic integral membrane proteins
about 100^110 amino acids long that form four putative
transmembrane K-helices [4]. So far more than 60 genes en-
coding SMR proteins have been identi¢ed in bacteria and
archaebacteria, many of which are pathogenic organisms [5].
EmrE, a SMR representative of Escherichia coli, has been
extensively studied and serves as the archetype for the whole
family [6]. EmrE catalyses the electrogenic e¥ux of a wide
variety of cationic aromatic hydrocarbons of varying size,
structure and charge, thereby rendering E. coli resistant to
these compounds [7]. Recent structural studies by electron
cryo-microscopy (cryo-EM) of two-dimensional (2D) crystals
of puri¢ed EmrE reconstituted in proteoliposomes have re-
vealed the three-dimensional (3D) architecture of the protein,
including the location of the substrate binding site, and the
translocation pathway within the protein [8^10]. The most
remarkable feature of the structure of EmrE is that it is a
homo-dimer composed of eight transmembrane K-helices ar-
ranged asymmetrically, a feature never observed before for
membrane proteins. In this review the current knowledge on
EmrE will be summarised and discussed with emphasis on its
structure and oligomeric state.
2. Biochemical properties
Assays in whole cells have shown that EmrE behaves as a
multidrug transporter and catalyses the e¥ux of a wide vari-
ety of cationic aromatic hydrocarbons of varying size, struc-
ture and charge, such as methyl viologen, ethidium acri£avine,
tetracycline and tetraphenylphosphonium (TPPþ) [7,11,12].
EmrE has been puri¢ed using either organic solvents [7] or
detergents [13] and reconstituted into phospholipid bilayers
and these proteoliposomes are capable of accumulating
[14C]methyl viologen by using a proton electrochemical gra-
dient. One useful property of EmrE is that it can be extracted
from membranes in a virtually pure form using chloroform^
methanol solutions, which allowed the development of a rapid
and simple reconstitution assay that has been used in many of
the experiments discussed below [7].
Cysteine scanning mutagenesis experiments indicate that
EmrE is composed of a tightly packed bundle of K-helices
without any continuous aqueous domains, suggesting that
substrates are translocated through a hydrophobic pathway
in the protein [14]. Further insights into the identity of the
amino acid residues in the substrate binding pocket and trans-
location pathway have been provided by site-directed muta-
genesis and chemical modi¢cation experiments. Seven of the
eight charged amino acid residues in EmrE are located in
putative loops and can be replaced with either cysteine or
other amino acids bearing the same charge without signi¢-
cantly a¡ecting transport activity [15]. The other charged res-
idue is Glu14, which is absolutely conserved in all EmrE ho-
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mologues and is located approximately in the centre of the
¢rst putative transmembrane domain (TMD 1) [5] ; this resi-
due is essential for activity and constitutes the site at which
both protons and cationic substrates bind in a mutually ex-
clusive fashion [15^17]. In addition, residues that are predicted
to be on the same face of TMD 1 as Glu14 are also essential
for e⁄cient Hþ-driven methyl viologen uptake into proteoli-
posomes and cells [18]. In the proposed mechanism of trans-
port, Glu14 residues from both monomers bind the substrate,
resulting in a conformation change so that the binding pocket
faces the periplasm; proton binding to both Glu14 residues
then induces the release of the substrate [15]. Recent data
from spin labelling studies con¢rm that TMDs 1 from each
monomer are in close proximity to each other [19]. Systematic
mutation of amino acid residues in TMD 2 and TMD 3 sug-
gests that these regions of EmrE are involved in substrate
recognition, but they are not absolutely essential for drug
transport [14]. No mutations to any residue in TMD 4 af-
fected substrate recognition or transport [20]. Amino acid
residues that cause decreased expression of EmrE have been
found in TMDs 2, 3 and 4, but not in TMD 1 [14,20].
3. Structural analysis
Since EmrE is a well-studied representative of the SMR
family and is small and apparently simple, the structure of
EmrE has received considerable attention over the last decade.
Hydropathy analysis of EmrE predicted four transmembrane
K-helices [7]. Given the relatively short length of EmrE (110
amino acids), this suggested that about 80% of the amino
acids are in helical conformation, a value that was supported
by evidence from Fourier transform infrared experiments of
EmrE reconstituted in lipid bilayers [21]. Further support was
provided by heteronuclear nuclear magnetic resonance spec-
troscopy studies on the whole protein in chloroform/metha-
nol/water mixtures [22] although EmrE is monomeric in this
solvent [23]. Because of the absence of any distinctive distri-
bution of positive charges in EmrE to suggest an orientation
more likely to face the cytoplasm according to the ‘positive
inside’ rule [24], the topology of EmrE in the membrane is
unclear and has yet to be determined unambiguously.
So far, the most detailed structural information on EmrE
has been provided by cryo-EM of 2D crystals. A projection
structure of EmrE at 7.0 AQ resolution was determined from
2D crystals obtained after reconstitution of puri¢ed His-
tagged EmrE at low lipid/protein ratios in dimyristoylphos-
phatidylcholine bilayers [8]. The repetitive unit in the crystal
was composed of eight K-helices arranged in an asymmetric
manner, indicating that the minimal functional unit for EmrE
was a dimer (Fig. 1B). EmrE in these 2D crystals is fully
functional as shown by the high-a⁄nity binding of [3H]TPPþ
when saturation binding experiments were performed on them
(Fig. 1A). We can conclude that TPPþ binds to the EmrE
within the crystals, and not just to a small non-crystalline
sub-population, because all the 2D crystals became disordered
after the addition of TPPþ [9]. Only one crystal from the
TPPþ soak was su⁄ciently ordered to allow indexing of the
di¡raction pattern, and this showed that the planar space
group had changed from c222 to p2, indicating that a change
in EmrE conformation had occurred. Well-ordered 2D crys-
tals of TPPþ-bound EmrE were grown by dialysis of deter-
gent-solubilised EmrE in the presence of excess TPPþ, and
these crystals were also found to have p2 symmetry [9]. Two
separate p2 projection maps of TPPþ-bound EmrE were de-
termined from two independent crystallisation experiments
and averaged; an averaged native EmrE projection structure
calculated from the c222 and p2221 crystals was then carefully
subtracted from the averaged TPPþ-bound form to create a
di¡erence density map. The interpretation of this di¡erence
density image suggested that TPPþ bound at the centre of
the EmrE dimer, and resulted in a small movement of at least
one tilted transmembrane K-helix (Fig. 1B).
Recently, the three-dimensional structure of EmrE was de-
termined to an in-plane resolution of 7.5 AQ by cryo-EM using
the p2 crystals of TPPþ-bound EmrE [10]. The structure cor-
responded to an EmrE dimer composed of eight transmem-
brane K-helices (Fig. 2) which, when viewed along an axis
perpendicular to the membrane, looked identical to the pre-
viously determined projection maps. Six tilted K-helices
Fig. 1. A: Saturation binding curve and Scatchard analysis (inset)
of [3H]TPPþ binding to 2D crystals (c222) of EmrE. A representa-
tive experiment is shown performed in duplicate (Kd = 2.3S 0.2 nM).
B: Density di¡erences between native EmrE and TPPþ-bound
EmrE. The crystallographic tetramer (grey contours) from the c222
projection map is shown overlaid with positive density di¡erences
(red contours) and negative di¡erences (blue contours) calculated
from a subtraction of the projection map for native EmrE from a
projection map of TPPþ-bound EmrE. The two asymmetric dimers
are outlined and the density di¡erence representing TPPþ is ringed
by a red circle and the density di¡erence arising from a conforma-
tion change caused by TPPþ binding is ringed by a green circle.
Features in the projection map are labelled according to the helix
nomenclature in Fig. 2. Adapted from [9] with permission.
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formed the walls of a chamber in which TPPþ was bound.
The remaining two K-helices were nearly perpendicular to the
membrane and were separated from the TPPþ binding cham-
ber by two of the highly tilted helices in the wall. The chamber
extends from one surface of the membrane to just past the
membrane centre, where it appears to be closed by the con-
vergence of helices F and H. The density for TPPþ appears as
an elongated mass, merging to the main density for helix H,
rather than as the predicted sphere, because the e¡ective res-
olution of the structure perpendicular to the membrane plane
Fig. 2. 3D structure of EmrE. A: View perpendicular to the membrane plane. B: Schematic view of EmrE perpendicular to the membrane
plane with K-helices represented as cylinders. C: View along the membrane plane. D: Slice through the structure viewed along the membrane
plane to emphasise the density representing TPPþ. Idealised helices (ribbons) were manually inserted into the density (mesh) without re¢nement.
Yellow helices form the substrate binding chamber whereas the two red helices are not in contact with TPPþ. E: Schematic model of EmrE
showing the access to the substrate binding chamber laterally from one lea£et of the lipid bilayer and from the aqueous medium. TPPþ is rep-
resented as a red sphere. Reproduced from [10] with permission from Oxford University Press.
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is only 16 AQ . The substrate binding chamber has two open-
ings, one facing the aqueous medium and the other facing
laterally the lipid bilayer (Fig. 2E), which would allow hydro-
phobic substrates in one lea£et of the E. coli inner membrane
to di¡use into the EmrE binding site. In addition, it is possible
that access to the lipid bilayer between the K-helices is re-
quired for larger substrates too big to ¢t into the binding
region de¢ned by TPPþ in the structure, thus allowing
EmrE to transport a larger range of substrates.
At the current resolution of our 3D structure we cannot
directly assign amino acid sequences to the observed densities.
Although we have made a tentative assignment of which four
densities represent each monomer, this was based upon a se-
ries of logical arguments and rationalisations [10]. We have
similarly used the limited biochemical [19] and cross-linking
[20] data to investigate possible models for the EmrE structure
(unpublished data). Although this was instructive, we could
not de¢ne one model as more likely than a small number of
other possible models for two reasons. Firstly, as mentioned
before, there are not enough published data to discriminate
between the models. Secondly, EmrE represents a new struc-
tural paradigm for a membrane protein, so we have no prior
knowledge of how two monomers of identical amino acid se-
quence can form an asymmetric dimer. It is probable that the
structures of the EmrE monomers within the asymmetric
dimer do not represent the structure of a free EmrE monomer
as would occur immediately after being synthesised in the cell.
Thus the monomers may only attain their ¢nal structure after
dimerisation has occurred.
4. Oligomeric state
It is critically important to de¢ne the oligomeric state of a
membrane protein if we are to understand how it functions,
but it can be extremely di⁄cult to determine [25]. We will
consider two stages of oligomerisation based upon the inter-
pretation of structural data from the 2D crystals. The primary
oligomeric state will be de¢ned as the number of monomers
required to form a substrate binding site and translocation
pathway through the membrane, but this would not necessar-
ily be the functional unit in vivo. The secondary oligomeric
state will be de¢ned as the oligomeric order found in vivo,
which could involve further oligomerisation either for reasons
of stability, or because it may be an obligatory requirement
for function. The importance of these distinctions in the olig-
omeric state is supported by good evidence to suggest that
many transporters, whose primary oligomeric state is a mono-
mer, appear to function as active transporters only once they
have formed dimers or tetramers in the membrane [26^29].
Three lines of evidence show that the primary oligomeric
state of EmrE is a dimer. The smallest repetitive structural
unit in 2D crystals of native EmrE is an asymmetric dimer [8].
Comparison of these structural units between 2D crystals with
and without TPPþ bound is consistent with one TPPþ mole-
cule binding in the middle of the asymmetric dimer [9]. This is
further corroborated by the 3D structure of TPPþ-bound
EmrE [10]. In addition, TPPþ binds to detergent-solubilised
EmrE with high a⁄nity in a molar ratio of 1:2 (TPPþ :EmrE)
[9] and this preparation has been shown by analytical ultra-
centrifugation to be a dimer (Butler and Tate, manuscript in
preparation). Both lines of biophysical evidence are supported
further by biochemical data in the form of cross-linking [20]
and hetero-oligomer formation [30] that indicate the presence
of EmrE dimers in the detergent-solubilised state.
The secondary oligomeric state of EmrE in vivo is less
certain. Negative-dominance studies, based upon measuring
proton-driven methyl viologen uptake into proteoliposomes,
clearly suggest that EmrE is present in the membrane in a
higher oligomeric state than a dimer [31]. Given that the pri-
mary oligomeric state of EmrE is a dimer, then the most
plausible state in vivo is therefore a tetramer, although even
higher oligomeric states cannot be entirely discounted. Two
tantalising possibilities for plausible EmrE tetramers are sug-
gested from 2D projection maps, because in all three di¡erent
crystal forms these tetramers are virtually identical [9]. In
projection, one crystallographic tetramer (dimer 1 and 3) is
related by a two-fold axis in the plane of the membrane, with
the two dimers closely interacting, but in opposite orientations
across the membrane (Fig. 3). The other tetramer (dimer 1
and 2) is related by a two-fold axis perpendicular to the mem-
brane and is formed by the interaction of helices E and D
from two adjacent dimers, which create a four-helix bundle
(Fig. 3). As these two dimers would have the same orientation
in the membrane, it is likely that this tetramer could well exist
in vivo in the inner bacterial membrane. At present we must
still categorise these oligomers as ‘crystallographic tetramers’,
although once we have assigned amino acid sequences to spe-
ci¢c densities, site-directed mutagenesis could be used to as-
sign the interfaces involved in tetramer formation, as has re-
cently been performed for the dimeric transporter, LacS [32].
It also remains to be seen whether there is a functional role
for a tetramer in vivo, or whether the dimer is fully capable of
catalysing drug e¥ux.
Fig. 3. EmrE forms two crystallographic tetramers in the 2D crys-
tals, with the asymmetric dimers related either by an in-plane two-
fold axis (arrow between dimers 1 and 3) or by a two-fold axis per-
pendicular to the membrane plane (ellipse between dimers 1 and 2).
Reproduced from [10] with permission from Oxford University
Press.
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5. Why is EmrE a dimer and why is it asymmetric?
One rationalisation for why EmrE is a dimer is simply
because monomeric EmrE is non-functional, either for sub-
strate binding or for transport. This is suggested from the
observation that at low protein concentration the EmrE dimer
dissociates with a concomitant loss of functional binding sites
[9]. With one TPPþ bound per dimer, it is reasonable to sug-
gest that dimerisation is concurrent with the formation of a
functional substrate binding site in EmrE. This is also sug-
gested from biochemical studies on hetero-oligomers [30]. The
reason why the EmrE dimer is asymmetric is less certain. One
possibility is that the asymmetry may result in slightly di¡er-
ent environments for the two essential Glu14 residues in the
dimer, which may be important in the transport mechanism.
Another possibility is that one or more conformations of a
monomer during the transport cycle may be unfavourable, or
unstable, but in the dimer that conformation is stabilised and
capable of performing its role in the catalytic mechanism.
These issues will only be resolved when we have an atomic
resolution structure for EmrE and the conformational states
of EmrE during the transport cycle have been de¢ned.
6. Note added in proof
A recent publication reported the structure of EmrE at 3.8
AQ resolution determined by X-ray di¡raction of 3D crystals
[Ma, C. and Chang, G. (2004) Proc. Natl. Acad. Sci. USA
101, 2852^2857]. The structure is remarkably di¡erent from
the structure we have determined by cryo-EM of 2D crystals.
Some of the di¡erences may have arisen due to the very di¡er-
ent crystallisation conditions needed to produce the 3D crys-
tals, which has resulted in di¡erent crystal contacts. In addi-
tion, no reference was made in the publication to functional
assays on expressed or puri¢ed EmrE.
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